Abstract 1669P
Background
Studies have shown that patients with cervical intraepithelial neoplasia (CIN) linked to human papillomavirus (HPV) experience shame and/or guilt due to the association of HPV with sexual transmission. Likewise, such feelings were also reported by cervical cancer (CC) patients. Understanding the similarities or differences in the relationship between guilt, shame, and quality of life (QoL) among these two groups might shed light on effective psychosocial interventions.
Methods
The study employed a cross-sectional design. Patients diagnosed with CIN (n=105, 11.42% CIN 1, 15.23% CIN 2, 58.09% CIN 3, 8.57% unknown) and CC (n=87, 16.09% stage 1, 17.24% stage 2, 36.78% stage 3, 8.04% stage 4, 8.04% were diagnosed with CIN that later progressed, 8.04% were uncertain about their stage at diagnosis, 5.74% unknown) who were recruited through social networks specific to CIN and CC patients completed self-report questionnaires assessing demographic information, medical history, QoL, and feelings of shame and guilt.
Results
The preliminary results revealed a significant negative association between both guilt and shame and QoL in both groups. However, no significant difference in QoL was found between CIN and CC patients (57.12, 52.26 respectively, p=0.1). Additionally, a significant higher level of guilt was reported by CIN patients (13.42) compared to CC patients (10.26) (d=0.58, p=0.0001). There was no significant difference in shame reported by CIN patients compared to CC patients (12.8, 11.37 respectively, p=0.07).
Conclusions
The findings underscore the detrimental role of shame and guilt in the perception of QoL of patients with CIN and CC. Addressing these negative feelings through targeted interventions may be crucial for improving overall well-being in these populations and enhancing their coping mechanisms. Further research involving a larger sample size may provide deeper insights into the differences and similarities between CIN and CC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HaBait Shel Bar - Israel Women's Cancer Association (RA) in collaboration with Ariel University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1627P - Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15
Presenter: Sarah Blanchet-Deverly
Session: Poster session 11
1628P - Factors influencing clinical and biological response in patients treated with [177Lu]Lu-PSMA-617 under France's early access program
Presenter: Vincent Habouzit
Session: Poster session 11
1629P - Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra)
Presenter: Kambiz Rahbar
Session: Poster session 11
1630P - A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)
Presenter: Sandra Van Wilpe
Session: Poster session 11
1632P - Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial
Presenter: Antoine Boué
Session: Poster session 11
1634P - Does lower serum testosterone predict metastases-free survival in nmCRPC patients treated with novel antiandrogens? A post-hoc analysis of SPARTAN and ARAMIS
Presenter: Xudong Ni
Session: Poster session 11
1635P - Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
Presenter: Andrea Knezevic
Session: Poster session 11